Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289305 | 0.89 | MAPT (0.34) | KDM4EGAAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL18121422 | 0.80 | GRIN2D (0.38) | ACHEKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL409685 | 0.80 | — | — | |
| SCHEMBL12801445 | 0.79 | GRIN2D (0.32) | ACHE | |
| SCHEMBL18665161 | 0.77 | ALDH1A1 (0.41) | ACHEKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL21230838 | 0.75 | GPR84 (0.40) | MAPTALDH1A1 | |
| SCHEMBL8368736 | 0.74 | KDM4E (0.31) | KDM4EGAAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL21842764 | 0.73 | EPHX1 (0.43) | MAPT | |
| SCHEMBL21231244 | 0.73 | ALDH1A1 (0.42) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL15087777 | 0.73 | MAPK1 (0.39) | KDM4EGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150899-A1 | CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF | CANWELL BIOTECH LIMITED (CN) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2020160054-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | CANWELL BIOTECH LIMITED (CN) | 2020-08-06 | — | — | WO | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| WO-2018075600-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8852630-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140127139-A1 | COMPOUNDS FOR DIAGNOSING DISEASES ASSOCIATED WITH THE EXPRESSION OF MUC5AC | GUERBET (FR) | 2014-05-08 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127139-A1 | COMPOUNDS FOR DIAGNOSING DISEASES ASSOCIATED WITH THE EXPRESSION OF MUC5AC | MUC1, VIP, FUCA1 | ACHE 4837/4885KDM4E 4880/4885GAA 445/4885 |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | ACHE 3653/4885KDM4E 4673/4885GAA 649/4885 |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | ACHE 3854/4885KDM4E 843/4885GAA 646/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | ACHE 3854/4885KDM4E 843/4885GAA 646/4885 |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | ACHE 1266/4885KDM4E 4795/4885GAA 157/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ACHE 4440/4885KDM4E 1208/4885GAA 1670/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | ACHE 4527/4885KDM4E 1252/4885GAA 459/4885 |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | ACHE 4530/4885KDM4E 4207/4885GAA 1159/4885 |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | ACHE 4783/4885KDM4E 3832/4885GAA 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.